Table 2 Demographic and tumor characteristics of study population (Caucasian women, n = 50)
Remained premenopausal (n = 24) | CIA (n = 26) | P-value | |
|---|---|---|---|
Mean age in years (± SD) | 36.7 (4.8) | 41.1 (4.0) | 0.001 |
Mean BMI kg/m2 (± SD) | 22.6 (2.9) | 23.8 (3.8) | 0.38 |
Smoking:* | 1.0 | ||
No | 20 | 20 | |
Yes | 4 | 4 | |
Mean age in years at menarche (± SD) | 13.1 (0.9) | 12.8 (1.2) | 0.44 |
Mean total duration of menstruation in years (± SD) | 23.4 (5.1) | 28.1 (4.8) | 0.005 |
Mean parity (± SD) | 1.4 (0.9) | 1.7 (1.0) | 0.49 |
Tumor stage: | 0.21 | ||
pT1 | 14 | 18 | |
pT2 | 7 | 8 | |
pT3 & pT4 | 3 | 0 | |
Nodal stage: | 0.82 | ||
pN0 | 11 | 11 | |
pN1 | 9 | 8 | |
pN2 & pN3 | 4 | 7 | |
Tumor grading:* | 0.23 | ||
1 | 3 | 0 | |
2 | 10 | 12 | |
3 | 10 | 14 | |
Estrogen receptor status: | 0.55 | ||
Positive | 15 | 19 | |
Negative | 9 | 7 | |
Progesterone receptor status: | 0.77 | ||
Positive | 16 | 16 | |
Negative | 8 | 10 | |
HER2 status: | 1.0 | ||
Positive | 4 | 4 | |
Negative | 20 | 22 | |
Tamoxifen therapy: | 0.77 | ||
Yes | 14 | 17 | |
No | 10 | 9 | |
Goserelin therapy: | 0.11 | ||
No | 9 | 16 | |
Concurrent to chemotherapy | 7 | 2 | |
Sequential to chemotherapy | 8 | 8 | |
Taxan-based chemotherapy: | 0.77 | ||
Yes | 14 | 17 | |
No | 10 | 9 | |